Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient [PDF]
Journal of Allergy and Clinical Immunology: GlobalA 29-year-old male patient had severe atopic dermatitis (AD) and alopecia universalis (AU) that could not be controlled by using classic therapy. He started taking upadacitinib and achieved an excellent response for both his AD and AU. Thus, upadacitinib
Mara Giavina-Bianchi, MD, PhD +1 more
doaj +3 more sources
Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report [PDF]
SAGE Open Medical Case Reports, 2023 Alopecia universalis is a severe, difficult to treat variant of alopecia areata that results in loss of hair on the scalp, eyebrows, eyelashes, and extremities.
Sarah Oliel +3 more
doaj +2 more sources
Improvement of atopic dermatitis and alopecia universalis with dupilumab: a case report [PDF]
Dermatology Reports, 2021 Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that showed significant improvement of atopic dermatitis (AD). Many reports have shown significant resolution of alopecia areata, alopecia universalis, and alopecia totalis after dupilumab ...
Lama Alotaibi +3 more
doaj +2 more sources
Hydroxychloroquine for granuloma annulare: A case report on secondary hair growth in alopecia universalis [PDF]
SAGE Open Medical Case Reports, 2023 Alopecia areata is an autoimmune disease resulting in non-scarring hair loss. Alopecia areata can progress to become alopecia totalis (loss of hair from the entire scalp) or alopecia universalis (loss of hair form the entire body), with the progression ...
Selena Osman, Danya Traboulsi
doaj +2 more sources
Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report [PDF]
SAGE Open Medical Case Reports, 2023 Alopecia areata is a non-scarring, autoimmune hair loss disorder that is associated with inflammatory bowel disease. Alopecia areata and inflammatory bowel disease may have a common pathogenic mechanism that involves the Janus kinase/STAT pathway.
Leah A Johnston +2 more
doaj +2 more sources
Myeloproliferative disorder associated with alopecia universalis [PDF]
JAAD Case ReportsMardeen S. Karim, MD +2 more
doaj +5 more sources
Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor [PDF]
Journal of Inflammation Research, 2023 Yan Teng,1 Yibin Fan,1 Danying Shang,1 Xiaohua Tao,1,* Dongsheng Sun2,* 1Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou ...
Teng Y, Fan Y, Shang D, Tao X, Sun D
doaj +2 more sources
Successful treatment of alopecia universalis with abrocitinib: a case report [PDF]
Journal of Dermatological Treatment, 2023 Abrocitinib, a highly selective inhibitor of Janus kinase 1 (JAK1), has been approved for the treatment of moderate-to-severe atopic dermatitis (AD).
Jie- Zhang, Ya-Gang Zuo
doaj +2 more sources
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report [PDF]
, 2014 For the last decade, the combination therapy of pegylated interferon (Peg-IFN) plus ribavirin (RBV) has been considered as the standard of care treatment for chronic hepatitis C virus (HCV) infection.
Bernardi M +7 more
core +3 more sources
Alopecia universalis after injection of messenger RNA COVID-19 vaccine. A case report [PDF]
IDCases, 2023 Messenger RNA vaccines against SARS-CoV-2 infection, or COVID-19 dramatically changed the landscape of the fight against COVID-19 pandemic. However, they might be associated with various side effects, such as myocarditis.
Kentaro Iwata, Makoto Kunisada
doaj +2 more sources